pyrroles has been researched along with Androgen-Independent Prostatic Cancer in 24 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 18 (75.00) | 24.3611 |
| 2020's | 6 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cerasuolo, M; Chiodelli, P; Coltrini, D; Giacomini, A; Grillo, E; Ligresti, A; Maccarinelli, F; Mussi, S; Presta, M; Rezzola, S; Ronca, R; Taranto, S; Turati, M | 1 |
| Birtle, AJ; Crabb, SJ; Downs, N; Dunkley, D; Ellis, M; Griffiths, G; Jones, RJ; Khoo, V; Light, M; Northey, J; Radford, M; Whitehead, A; Wilding, S | 1 |
| Fujiwara, K; Funakoshi, D; Hara, M; Inoue, S; Obinata, D; Takahashi, S; Takayama, K; Yamamoto, S | 1 |
| Banelli, B; Barboro, P; Fiordoro, S; Ghedira, LC; Iervasi, E; Izzotti, A; Kohnke, FH; Ponassi, M; Rosano, C; Toumia, IB; Vargas, GC | 1 |
| Campbell, H; Davies, BR; De Velasco, MA; Hatanaka, Y; Kim, Y; Klein, S; Kura, Y; MacLeod, AR; Nishio, K; Sakai, K; Sugimoto, K; Uemura, H; Yoshikawa, K | 1 |
| Banerji, U; Bianchini, D; Carreira, S; Crespo, M; de Bono, JS; Figueiredo, I; Flohr, P; Hall, E; Kolinsky, MP; Lambros, M; Leonard, L; Luo, J; Mateo, J; Mehra, N; Michalarea, V; Miranda, S; Nava Rodrigues, D; Plymate, S; Porta, N; Raynaud, FI; Rescigno, P; Riisnaes, R; Ruddle, R; Sharp, A; Slade, R; Swales, KE; Tovey, H; Tunariu, N; Welti, J; Zafeiriou, Z | 1 |
| Bahl, A; Birtle, AJ; Crabb, SJ; Downs, N; Dunkley, D; Elliott, T; Griffiths, G; Jagdev, S; Jones, RJ; Khoo, V; Kumar, S; Light, M; Martin, K; Marwood, E; Northey, J; Robinson, A; Rooney, C; Salinas-Souza, C; Shaw, E; Stephens, C; Sundar, S; Westbury, C; Whitehead, A; Wilding, S | 1 |
| Bergh, A; Bergström, SH; Bovinder-Ylitalo, E; Lerner, UH; Nordstrand, A; Thysell, E; Widmark, A; Wikström, P | 1 |
| Bollag, G; Guan, W; Hu, J; Tan, P; Tang, Z; West, BL; Wu, L; Xu, H; Yang, L | 1 |
| Barata, PC; Cooney, M; Dreicer, R; Garcia, JA; Gupta, R; Mendiratta, P | 1 |
| Beraldi, E; Crafter, C; Davies, BR; Fazli, L; Gleave, ME; Kim, S; Lamoureux, F; Thaper, D; Thomas, C; Zoubeidi, A | 1 |
| Armstrong, AJ; Chen, I; Chow-Maneval, E; Galsky, MD; Lechuga, M; Leopold, L; Michaelson, MD; Mooney, DJ; Paolini, J; Pond, GR; Smith, MR; Sonpavde, G; Wang, SL; Wood, BA | 1 |
| Adler, D; Andren, O; Biskup, S; Boehm, D; Braun, M; Bubendorf, L; Kirfel, J; Kristiansen, G; Menon, R; Offermann, A; Perner, S; Queisser, A; Rüenauver, K; Ruiz, C; Svensson, M; Vogel, W; Wernert, N; Zellweger, T | 1 |
| Armstrong, AJ; Chen, I; Chow-Maneval, E; Clarke, SJ; Lechuga, M; Michaelson, MD; Paolini, J; Pond, GR; Smith, MR; Sonpavde, G; Templeton, AJ; Vardy, JL; Wang, SL | 1 |
| Byun, SS; Cheon, J; Hong, SK; Jeong, SJ; Lee, SE; Moon, du G; Oh, MM; Park, HS; Yoon, CY | 1 |
| Flores-Morales, A; Hekmat, O; Hjorth-Jensen, K; Iglesias-Gato, D; Jiang, N; Ke, B; Kruse, T; Niu, Y; Olsen, JV; Wang, C; Wei, W; Yan, B | 1 |
| Cordonnier, T; Crafter, C; Davies, BR; Fazli, L; Gleave, ME; Kim, S; Toren, P; Zoubeidi, A | 1 |
| Froehner, M; Wirth, MP | 1 |
| Fujisawa, M; Miyake, H; Nishikawa, M | 1 |
| Argyros, O; Asvos, X; Davos, CH; Fokas, D; Karampelas, T; Papakyriakou, A; Sayyad, N; Tamvakopoulos, C; Tzakos, AG; Varela, A | 1 |
| Aburatani, H; Fujimura, T; Fujiwara, K; Fukuda, N; Homma, Y; Inoue, S; Nagase, H; Obinata, D; Suzuki, T; Takahashi, S; Takayama, K; Tsutsumi, S; Urano, T | 1 |
| Cheng, T; Chi, KN; Eigl, BJ; Eliasziw, M; North, S; Parimi, S; Ruether, D; Trudeau, M; Winquist, E | 1 |
| Birtle, AJ; Crabb, SJ; Downs, N; Ellis, M; Griffiths, G; Jones, RJ; Khoo, V; Ksiazek, L; Maishman, T; Martin, K; Ratcliffe, I; Thompson, S | 1 |
| Byun, SS; Hong, SK; Jeong, CW; Jeong, SJ; Kwak, C; Lee, SE; Yoon, CY | 1 |
8 trial(s) available for pyrroles and Androgen-Independent Prostatic Cancer
| Article | Year |
|---|---|
Overall Survival Update for Patients with Metastatic Castration-resistant Prostate Cancer Treated with Capivasertib and Docetaxel in the Phase 2 ProCAID Clinical Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Disease-Free Survival; Docetaxel; Humans; Male; Nitriles; Phenylthiohydantoin; Phosphatidylinositol 3-Kinases; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Proto-Oncogene Proteins c-akt; Pyrimidines; Pyrroles; Receptors, Androgen; Treatment Outcome | 2022 |
A phase I dose-escalation study of enzalutamide in combination with the AKT inhibitor AZD5363 (capivasertib) in patients with metastatic castration-resistant prostate cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Humans; Male; Nitriles; Phenylthiohydantoin; Phosphatidylinositol 3-Kinases; Prostatic Neoplasms, Castration-Resistant; Proto-Oncogene Proteins c-akt; Pyrimidines; Pyrroles; Treatment Outcome | 2020 |
Pan-AKT Inhibitor Capivasertib With Docetaxel and Prednisolone in Metastatic Castration-Resistant Prostate Cancer: A Randomized, Placebo-Controlled Phase II Trial (ProCAID).
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Docetaxel; Double-Blind Method; Humans; Male; Middle Aged; Neoplasm Metastasis; Prednisolone; Progression-Free Survival; Prostatic Neoplasms, Castration-Resistant; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrimidines; Pyrroles; Time Factors; United Kingdom | 2021 |
Phase I/II study evaluating the safety and clinical efficacy of temsirolimus and bevacizumab in patients with chemotherapy refractory metastatic castration-resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzodiazepines; Bevacizumab; Biomarkers, Tumor; Disease Progression; Drug Resistance, Neoplasm; Follow-Up Studies; Gene Expression Regulation, Neoplastic; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Prostatic Neoplasms, Castration-Resistant; Pyrroles; Salvage Therapy; Sirolimus; Tissue Distribution; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A | 2019 |
Radiographic progression by Prostate Cancer Working Group (PCWG)-2 criteria as an intermediate endpoint for drug development in metastatic castration-resistant prostate cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free Survival; Docetaxel; Drug Discovery; Gossypol; Humans; Indoles; Male; Prednisone; Prostatic Neoplasms, Castration-Resistant; Pyrroles; Radiography; Retrospective Studies; Sunitinib; Survival Rate; Taxoids; Time Factors | 2014 |
Prognostic impact of the neutrophil-to-lymphocyte ratio in men with metastatic castration-resistant prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Alkaline Phosphatase; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Docetaxel; Hemoglobins; Humans; Indoles; Inflammation; Kaplan-Meier Estimate; L-Lactate Dehydrogenase; Lymphocyte Count; Lymphocytes; Male; Middle Aged; Neutrophils; Placebos; Prednisone; Prognosis; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Pyrroles; Retrospective Studies; Sunitinib; Taxoids | 2014 |
Sunitinib maintenance therapy after response to docetaxel in metastatic castration resistant prostate cancer (mCRPC).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Disease Management; Docetaxel; Follow-Up Studies; Humans; Indoles; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Prognosis; Prostatic Neoplasms, Castration-Resistant; Pyrroles; Sunitinib; Survival Rate; Taxoids | 2016 |
ProCAID: a phase I clinical trial to combine the AKT inhibitor AZD5363 with docetaxel and prednisolone chemotherapy for metastatic castration resistant prostate cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Dose-Response Relationship, Drug; Humans; Male; Maximum Tolerated Dose; Middle Aged; Prednisolone; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Proto-Oncogene Proteins c-akt; Pyrimidines; Pyrroles; Taxoids | 2017 |
16 other study(ies) available for pyrroles and Androgen-Independent Prostatic Cancer
| Article | Year |
|---|---|
FGFR blockade by pemigatinib treats naïve and castration resistant prostate cancer.
Topics: Androgen Antagonists; Animals; Humans; Male; Mice; Morpholines; Prostatic Neoplasms, Castration-Resistant; Pyrimidines; Pyrroles; Receptor, Fibroblast Growth Factor, Type 2 | 2022 |
Antitumor effects of pyrrole-imidazole polyamide modified with alkylating agent on prostate cancer cells.
Topics: Alkylating Agents; Cell Line, Tumor; Humans; Imidazoles; Male; Nylons; Prostatic Neoplasms, Castration-Resistant; Pyrroles; Receptors, Androgen | 2022 |
Two calix[4]pyrroles as potential therapeutics for castration-resistant prostate cancer.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Humans; Leukocytes, Mononuclear; Male; Mice; Mice, Inbred BALB C; Porifera; Prostatic Neoplasms, Castration-Resistant; Pyrroles | 2022 |
Targeting castration-resistant prostate cancer with androgen receptor antisense oligonucleotide therapy.
Topics: Animals; Antineoplastic Agents; Disease Models, Animal; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Oligonucleotides, Antisense; Phosphatidylinositol 3-Kinases; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Proto-Oncogene Proteins c-akt; Pyrimidines; Pyrroles; Receptors, Androgen; Signal Transduction; Transcriptome | 2019 |
Inhibition of the insulin-like growth factor-1 receptor potentiates acute effects of castration in a rat model for prostate cancer growth in bone.
Topics: Animals; Apoptosis; Bone Neoplasms; Cell Proliferation; Disease Models, Animal; Humans; Male; Neoplasm Staging; Phosphorylation; Prognosis; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Pyrimidines; Pyrroles; Rats; Receptor, IGF Type 1; Receptors, Somatomedin; Signal Transduction; Survival Rate; Tumor Cells, Cultured | 2017 |
Inhibition of TAMs improves the response to docetaxel in castration-resistant prostate cancer.
Topics: Aminopyridines; Animals; Antineoplastic Agents; Cell Line; Cytokines; Docetaxel; Humans; Macrophages; Male; Mice; Prostatic Neoplasms, Castration-Resistant; Pyrroles; Receptor, Macrophage Colony-Stimulating Factor | 2019 |
Synergistic targeting of PI3K/AKT pathway and androgen receptor axis significantly delays castration-resistant prostate cancer progression in vivo.
Topics: Androgen Receptor Antagonists; Anilides; Animals; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Disease Progression; Drug Therapy, Combination; Humans; Male; Mice; Mice, Nude; Neoplasms, Experimental; Nitriles; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Prostatic Neoplasms, Castration-Resistant; Proto-Oncogene Proteins c-akt; Pyrimidines; Pyrroles; Receptors, Androgen; Signal Transduction; Tosyl Compounds; Xenograft Model Antitumor Assays | 2013 |
MED15, encoding a subunit of the mediator complex, is overexpressed at high frequency in castration-resistant prostate cancer.
Topics: Aged; Androgens; Cell Line, Tumor; Cell Proliferation; Gene Expression Regulation, Neoplastic; Glycine; Humans; In Situ Hybridization, Fluorescence; Male; Mediator Complex; Middle Aged; Prostatic Neoplasms, Castration-Resistant; Pyrroles; Receptors, Androgen; Signal Transduction | 2014 |
Synergistic antitumor effect of NVP-BEZ235 and sunitinib on docetaxel-resistant human castration-resistant prostate cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Caspases; Cell Line, Tumor; Docetaxel; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Humans; Imidazoles; Indoles; Male; Phosphorylation; Prostatic Neoplasms, Castration-Resistant; Proto-Oncogene Proteins c-akt; Pyrroles; Quinolines; Sunitinib; Taxoids; Vascular Endothelial Growth Factor Receptor-2 | 2014 |
In vivo quantitative phosphoproteomic profiling identifies novel regulators of castration-resistant prostate cancer growth.
Topics: Androgens; Animals; Cell Line, Tumor; Cell Proliferation; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Phosphorylation; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Proteome; Proteomics; Pyrazoles; Pyrroles; Receptors, Androgen; Signal Transduction | 2015 |
Combination AZD5363 with Enzalutamide Significantly Delays Enzalutamide-resistant Prostate Cancer in Preclinical Models.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Humans; Male; Nitriles; Phenylthiohydantoin; Prostate; Prostatic Neoplasms, Castration-Resistant; Proto-Oncogene Proteins c-akt; Pyrimidines; Pyrroles; Receptors, Androgen; Signal Transduction; Treatment Outcome; Xenograft Model Antitumor Assays | 2015 |
Simultaneous targeting of the Akt and androgen receptor pathways.
Topics: Cell Proliferation; Drug Resistance, Neoplasm; Humans; Male; Phenylthiohydantoin; Prostate; Prostatic Neoplasms, Castration-Resistant; Pyrimidines; Pyrroles | 2015 |
Enhanced Sensitivity to Sunitinib by Inhibition of Akt1 Expression in Human Castration-resistant Prostate Cancer PC3 Cells Both In Vitro and In Vivo.
Topics: Animals; Antineoplastic Agents; Humans; Indoles; Male; Mice; Prostatic Neoplasms, Castration-Resistant; Proto-Oncogene Proteins c-akt; Pyrroles; Sunitinib; Tumor Cells, Cultured | 2015 |
Peptide-Drug Conjugate GnRH-Sunitinib Targets Angiogenesis Selectively at the Site of Action to Inhibit Tumor Growth.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Cell Proliferation; Drug Design; Gonadotropin-Releasing Hormone; Humans; Indoles; Male; Mice; Prostatic Neoplasms, Castration-Resistant; Pyrroles; Receptors, LHRH; Sunitinib; Xenograft Model Antitumor Assays | 2016 |
Targeting Oct1 genomic function inhibits androgen receptor signaling and castration-resistant prostate cancer growth.
Topics: Androgen Receptor Antagonists; Animals; Cell Line, Tumor; Cell Proliferation; Coenzyme A Ligases; Genomics; Humans; Imidazoles; Male; Mice; Mice, Nude; Molecular Targeted Therapy; Nylons; Octamer Transcription Factor-1; Prostatic Neoplasms, Castration-Resistant; Pyrroles; Receptors, Androgen; Signal Transduction; Transfection | 2016 |
The role of hypoxia-inducible factor-1α and -2α in androgen insensitive prostate cancer cells.
Topics: Antineoplastic Agents; Basic Helix-Loop-Helix Transcription Factors; Blotting, Western; Cell Line, Tumor; Cell Movement; Cell Survival; Cyclin-Dependent Kinase Inhibitor p21; Docetaxel; Dose-Response Relationship, Drug; Gene Expression Regulation, Neoplastic; Glucose Transporter Type 1; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Indoles; Insulin-Like Growth Factor I; Male; Niacinamide; Phenylurea Compounds; Prostatic Neoplasms, Castration-Resistant; Proto-Oncogene Proteins c-met; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Sorafenib; Sunitinib; Taxoids; Zinc Sulfate | 2013 |